CTI-CTI Dimer Payloads for Antibody Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face limitations in disease indications and treatment profiles due to the properties of drugs like auristatins, maytansines, and duocarmycin analogs, necessitating the development of novel ADCs with improved properties for effective cancer treatment.
Innovation Solution
The development of CTI/CTI-based dimers and their derivatives, including seco forms, connected to linker molecules for attachment to antibodies, forming cytotoxic antibody drug conjugates with enhanced chemical reactivity and biological properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing ADC drugs (auristatins, maytansines, duocarmycin analogs) are used, then ADCs can be formed for cancer treatment, but disease indications and treatment profiles are limited
Solution Approach 1:
The patent segments the existing ADC structure by replacing the traditional single drug moiety with a dimeric payload consisting of two CTI units connected by a linker. This segmentation allows the first CTI unit to provide DNA alkylation activity for cytotoxicity while the second CTI unit provides ADC formation capability through its hydroxyl group, thereby expanding treatment profiles without compromising cancer treatment efficacy
Solution Approach 2:
The dimeric CTI payload structure embodies multi-functionality: one CTI unit serves as the cytotoxic agent for DNA alkylation, while the other CTI unit serves as the conjugation handle for ADC formation. This universal design simultaneously addresses both cancer killing activity and ADC stability, resolving the contradiction between versatility and reliability
2Reliability
If bifunctional cross linkers with two reactive alkylation motifs are used, then DNA cross-linking activity is enhanced, but selective treatment capability is reduced
Solution Approach 1:
The patent applies local quality by differentiating the functional properties of the two CTI units within the dimer. The first CTI unit is designed with optimal DNA alkylation properties for potent cytotoxicity, while the second CTI unit is configured with a hydroxyl group specifically for ADC conjugation. This localized functional differentiation enables selective treatment by directing the cytotoxic activity toward cancer cells while using the antibody component for target selection
Solution Approach 2:
The patent introduces an intermediary structure - the dimeric payload with a dedicated conjugation handle - that mediates between the antibody targeting system and the cytotoxic CTI unit. This intermediary enables selective delivery of the potent DNA alkylating agent to cancer cells through ADC mechanisms, resolving the contradiction between potency and selectivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CTI/CTI-based dimers provide distinctive drug entities with improved cytotoxicity and specificity, enhancing the efficacy of ADCs in treating cancer and other proliferative diseases by optimizing drug release and intracellular trafficking.
Implementation Method 1
These compounds are active DNA cross linkers, whereas compounds with only one alkylation motif (e.g., duocarmycins) are DNA mono-alkylators
Implementation Method 2
The prodrug-to-active drug conversion for the bifunctional cross linkers is exemplified in the CBI dimer shown below
Data Source
AI summary
The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1–L1–T–L2–F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.